Table 2.
Clinical outcomes of patients with HBV-related acute-on-chronic liver failure on tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment
| Outcome, n (%) | TAF 25 mg | TDF 300 mg | ETV 0.5 mg | P value |
|---|---|---|---|---|
| (n = 10) | (n = 10) | (n = 20) | ||
| Mortality or transplantation | ||||
| Within 28 days | 1 (10) | 3 (30) | 2 (10) | 0.504 |
| Within 3 months | 2 (20) | 4 (40) | 3 (15) | 0.320 |
| Within 48 weeks | 2 (20) | 4 (40) | 3 (15) | 0.320 |
| Liver-related complications (first 3 months) | ||||
| Ascites | 7 (70) | 7 (70) | 13 (65) | 0.945 |
| Spontaneous bacterial peritonitis | 6 (60) | 6 (60) | 11 (55) | 0.950 |
| Infection during treatment | 3 (30) | 4 (40) | 7 (35) | 0.896 |
| Gastrointestinal hemorrhage | 0 (0) | 1 (10) | 1 (5) | 0.591 |
| Hepatorenal syndrome | 1 (10) | 2 (20) | 0 (0) | 0.244 |
| Hepatic encephalopathy | 0 (0) | 2 (20) | 1 (5) | 0.299 |